PositiveID Corporation Announces
Lawrence Livermore National
Laboratory Evaluation
of PositiveID's FireflyDX
Delray
Beach, FL -- January 22,
2018 -- InvestorsHub
NewsWire -- PositiveID Corporation (OTC:
PSID), a life sciences company focused on detection and
diagnostics,
and its
ExcitePCR Corporation subsidiary, announced today
that Lawrence Livermore
National Laboratory has completed an analysis and report
of
the
FireflyDX
real-time
polymerase chain
reaction (PCR)
pathogen
detection prototype.
PositiveID and ExcitePCR have
published the
report on their
websites.
The FireflyDX prototype
system , faster and less
expensively than existing devices.need
(POC/PON)point of
care/athogens
at the point of , fully automated,
lab quality, real-time device able to process samples and detect
pportableis
designed to be a
"We
are
extremely
proud
to demonstrate the progress we've made in the development of
FireflyDX, which, we believe, better
positions ExcitePCR for the appropriate funding to move FireflyDX
to its next stage and closer to
commercialization,"
stated
Lyle L.
Probst, CEO and
President of
ExcitePCR.
"The
opportunity to show the FireflyDX prototype system in
action and present data
that
validates
our
detection capabilities and demonstrates
our
ability to compete against industry-standard, lab-based
equipment was a high point for
the ExcitePCR team," said Dr. Kimothy
Smith, Chief Science Officer of
ExcitePCR.
FireflyDX's
applications include the near
real-time detection of
pathogenic organisms
in
verticle markets addressing
human
clinical
applications,
infectious
diseases,
and
hospital
acquired infections; agricultural and
food screening in both domestic sectors and developing countries;
and detection of biological agents associated with
weapons of mass destruction.
The report, which has been
partially redacted due to the proprietary
nature of certain
content,
was
prepared under agreement between PositiveID and Lawrence
Livermore National
Laboratory.
Disclaimer:
This
document may contain research results that are experimental in
nature, and neither the United States Government, any agency
thereof, Lawrence Livermore National Security, LLC, nor any of its
employees makes any warranty, express or implied, or assumes any
legal liability or responsibility for the accuracy, completeness,
or usefulness of any information,
apparatus, product, or process disclosed, or represents that its
use would not infringe privately owned rights.
Reference to any specific commercial
product, process, or service by trade name, trademark,
manufacturer, or otherwise does not constitute or imply an
endorsement or recommendation by the U.S. Government or Lawrence
Livermore National Security, LLC. The views
and opinions of authors expressed herein do not necessarily reflect
those of the U.S. Government or Lawrence Livermore National
Security, LLC and will not be used for advertising or
product endorsement purposes.
About PositiveID
Corporation
PositiveID
Corporation is a life sciences tools and diagnostics company with
an extensive patent portfolio. PositiveID develops biological
detection and diagnostics systems, specializing in the development
of microfluidic systems for the automated preparation of and
performance of biological assays. PositiveID is also a leader in
the mobile technology vehicle market, with a focus on the
laboratory market and homeland security. For more information on
PositiveID, please visit http://www.psidcorp.com, or connect with
PositiveID on Twitter, Facebook or LinkedIn.
On August 24, 2017,
PositiveID Corporation and its wholly-owned subsidiary PositiveID
Diagnostics, Inc. (collectively, the "Seller"), entered into an
Asset Purchase Agreement ("APA") with ExcitePCR Corporation.
Pursuant to the APA, at closing, the Seller will sell and deliver
to ExcitePCR all assets used in connection with the operation of the
FireflyDX technology. For more information on the APA, please read
PositiveID's Form 8-K filed on August 28, 2017, which can be
found here.
Statements about
PositiveID's ("Company") future expectations,
including the likelihood that FireflyDX is designed to be
a portable, fully automated, lab quality, real-time device able to
process samples and detect pathogens at the POC/PON, faster and
less expensively than existing devices; the
likelihood that demonstrating the
progress the Company has made in the development
of FireflyDX better positions ExcitePCR for the appropriate funding
to move FireflyDX to its next stage and closer to
commercialization; the likelihood that
FireflyDX's applications include the near real-time detection
of pathogenic organisms in verticle markets addressing human
clinical applications, infectious diseases, and hospital acquired
infections; agricultural and food screening in both domestic
sectors and developing countries; and detection of biological
agents associated with weapons of mass destruction;
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934, and as that term is defined in the
Private Litigation Reform Act of 1995. Such forward-looking
statements involve risks and uncertainties and are subject to
change at any time, and PositiveID's actual results could
differ materially from expected results. These risks and
uncertainties include, without limitation, the Company's
ability to attract new customers and retain existing
customers; the Company's ability to target the
professional healthcare market; the Company's ability to raise
capital; the Company's ability to complete the testing and
development of FireflyDX; the likelihood that the Company and
ExcitePCR will close the APA; as well as other risks.
Additional information about these and other factors that could
affect the Company's business is set forth in the Company's various
filings with the Securities and Exchange Commission, including
those set forth in the Company's 10-K filed on March 31,
2017, and 10-Qs filed on November 13, 2017, August 14, 2017, and
May 15, 2017, under the caption "Risk Factors." The
Company undertakes no obligation to update or release any revisions
to these forward-looking statements to reflect events or
circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by
law.
Contact:
PositiveID
Corporation
Allison
Tomek
(561)
805-8044
atomek@psidcorp.com